277 related articles for article (PubMed ID: 29177164)
1. Medical Therapy of Gastrointestinal Neuroendocrine Tumors.
Öberg K
Visc Med; 2017 Oct; 33(5):352-356. PubMed ID: 29177164
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Maqsood MH; Tameez Ud Din A; Khan AH
Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
[TBL] [Abstract][Full Text] [Related]
4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
6. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
8. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.
Hirmas N; Jadaan R; Al-Ibraheem A
Nucl Med Mol Imaging; 2018 Jun; 52(3):190-199. PubMed ID: 29942397
[TBL] [Abstract][Full Text] [Related]
9. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Yordanova A; Ahrens H; Feldmann G; Brossart P; Gaertner FC; Fottner C; Weber MM; Ahmadzadehfar H; Schreckenberger M; Miederer M; Essler M
Clin Nucl Med; 2019 May; 44(5):e329-e335. PubMed ID: 30932975
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525
[TBL] [Abstract][Full Text] [Related]
12. Management of neuroendocrine tumors: current and future therapies.
Öberg KE
Expert Rev Endocrinol Metab; 2011 Jan; 6(1):49-62. PubMed ID: 30764035
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
14. How I treat neuroendocrine tumours.
Kiesewetter B; Raderer M
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817134
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons.
Bundschuh RA; Habacha B; Lütje S; Essler M
J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31527438
[TBL] [Abstract][Full Text] [Related]
18. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
[TBL] [Abstract][Full Text] [Related]
20. Management of well-differentiated neuroendocrine tumors.
Tella SH; Starr JS; Kommalapati A; Sonbol MB; Halfdanarson TR
Clin Adv Hematol Oncol; 2021 Sep; 19(9):582-593. PubMed ID: 34495022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
